Aptinyx to Participate in Upcoming Virtual Investor Conferences
Aptinyx Inc. (Nasdaq: APTX) announced participation in two investor conferences. A presentation at the Stifel 2020 Virtual Healthcare Conference is scheduled for November 17, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat will be available during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020, accessible on the company’s IR website. Aptinyx focuses on developing therapies for brain and nervous system disorders, with three product candidates in clinical development for conditions like chronic pain and PTSD.
- None.
- None.
EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences:
- A presentation during the Stifel 2020 Virtual Healthcare Conference at 1:20 p.m. ET on Tuesday, November 17, 2020; and
- A pre-recorded fireside chat during the Piper Sandler 32nd Annual Healthcare Conference. The virtual conference will be held from December 1-3, 2020. The fireside chat will be available on the company’s IR website.
These presentations will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
